High barrier-to-entry API, finished injectables to drive growth in 2017: ScinoPharm CEO

Tainan-headquartered ScinoPharm Taiwan (1789, TaiEx), the country’s leading API manufacturer, will continue its strategy of producing high barrier-to-entry API while vertically expanding its offering to encompass the manufacturing of finished injectable products, reported Chen Yung-fa, ScinoPharm’s President & CEO in a recent interview with PharmaBoardroom.

Read more

TaiGen Biotechnology and HEC Pharmaceutical execute equity purchase agreement for HCV-focused JV

Taipei, Taiwan-headquartered TaiGen Biotechnology Co., Ltd. announced today that its wholly owned Chinese subsidiary, TaiGen Biopharmaceuticals Co. (Beijing), Ltd. has executed an equity purchase agreement to sell its 9% equity stake in Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd., a joint venture company between TGBJ and HEC, to Chinese pharma company YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Read more

Pitfalls of technology licensing, urgent need for training among issues covered at panel discussion on Taiwan’s biologics business environment

To take advantage of its strong science base and a growing number of small innovative companies, Taiwan’s burgeoning biopharmaceutical industry will need to start planning now to develop personnel skilled enough in GMP manufacturing and clinical trials to meet the demands and rigors of such a highly technical field.

Read more

Baxter and Taiwan’s ScinoPharm announce partnership for generic injectable cancer drugs

Baxter International Inc. (NYSE: BAX) and ScinoPharm Taiwan, Ltd. (TWSE: 1789) last week announced a strategic partnership to develop, manufacture and commercialize five injectable generic drugs used in a range of cancer treatments, including lung cancer, multiple myeloma and breast cancer, as well as medication to treat nausea and vomiting, common side effects of chemotherapy.

Read more